Journals / Eurasian Journal of Family Medicine / 2020 / Cilt: 9 - Sayı: 4

European Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed?

Avrupa Kardiyoloji Derneği/Avrupa Ateroskleroz Derneği 2019 Dislipidemi Tedavi Kılavuzu: Değişen Neler Var?

Pages
187–198
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the light of those information the recommendation for patients at very high risk was changed as a low density lipoprotein cholesterol goal of

📌 3 Key Takeaways

🎯
Objective & Hypothesis:After 3 years, European Society of Cardiology and the European Atherosclerosis Society published the new guideline for the management of dyslipidemias on August 2019.
📊
Key Findings & Data:Comparing with the 2016 version, based on the latest prospective studies, randomized trials and Mendelian randomization studies, there are major changes in the recommendations; especially in the areas of total cardiovascular risk estimation, treatment targets and management of treatment, focusing on the combination therapy.
💡
Conclusion & Impact:In the light of those information the recommendation for patients at very high risk was changed as a low density lipoprotein cholesterol goal of
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

After 3 years, European Society of Cardiology and the European Atherosclerosis Society published the new guideline for the management of dyslipidemias on August 2019. Comparing with the 2016 version, based on the latest prospective studies, randomized trials and Mendelian randomization studies, there are major changes in the recommendations; especially in the areas of total cardiovascular risk estimation, treatment targets and management of treatment, focusing on the combination therapy. Aforementioned studies indicated that it is possible to prevent atherosclerotic cardiovascular diseases by reducing low density lipoprotein cholesterol as early as and as much as possible since there is a correlation between the concentration of low density lipoprotein cholesterol in the blood and the risk of atherosclerotic cardiovascular diseases. In the light of those information the recommendation for patients at very high risk was changed as a low density lipoprotein cholesterol goal of

Özet

Üç yıl aradan sonra, Ağustos 2019'da Avrupa Kardiyoloji Derneği ve Avrupa AterosklerozDerneği, dislipidemilerin tedavisine ilişkin yeni kılavuzunu yayınladı. 2016 versiyonu ile karşılaştırıldığında, yapılan en son prospektif çalışmalar, randomize çalışmalar ve Mendel randomizasyonu çalışmalarından elde edilen bulgular uyarınca, özellikle toplam kardiyovasküler risk tahmini, tedavi hedefleri ve kombinasyon tedavileri odağında tedavi yönetimi alanlarında olmak üzereönemli değişiklikler göze çarpmaktadır. Bahse konu çalışmalarda kandaki düşük yoğunluklu lipoprotein kolesterol miktarı ile aterosklerotik kardiyovasküler hastalık geçirme riski arasında korelasyon bulunduğundan dolayı, düşük yoğunluklu lipoprotein kolesterol düzeyini mümkün olduğu kadar erken zamanda ve mümkün olduğu kadar fazla miktarda düşürerek aterosklerotik kardiyovasküler hastalıkların önlenmesinin mümkün olduğu belirtilmektedir. Bu bilgiler ışığında, çok yüksek risk grubundaki hastalarda daha önceki kılavuzda

🔖

Cite This Article

DOĞANER, Y. Ç., AYDOĞAN, Ü., DOĞRUL, H. (2022). European Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed?. Eurasian Journal of Family Medicine, Cilt: 9 - Sayı: 4, 187–198. https://ajindex.com/articles/508320

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Türkiye Endokrinoloji ve Metabolizma Derneği [internet]. Dislipidemi tanı ve tedavi kılavuzu. [cited 2019 March 19]. Available from: http://temd.org.tr/admin/uplo ads/tbl_kilavuz/20190506163 838- 2019tbl_kilavuz61855bdd04. pdf 2. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020
  2. 41(1):111-88. 3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016
  3. 37(39):2999-3058. 4. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012
  4. 33(13):1635-701. doi: 10.1093/eurheartj/ehs092. 5. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010
  5. 376(9753):1670-81. doi: 10.1016/S0140- 6736(10)61350-5. 6. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015
  6. 372(25):2387-97. 7. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017
  7. 376(18):1713-22. 8. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018
  8. 379(22):2097-107. 9. Bhatt DL, Steg PG, Miller M,Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019
  9. 380(1):11-22. doi: 10.1056/NEJMoa1812792.